Foghorn Therapeutics (FHTX) Accounts Payables (2020 - 2025)
Historic Accounts Payables for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $9.8 million.
- Foghorn Therapeutics' Accounts Payables fell 1245.21% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 1245.21%. This contributed to the annual value of $8.5 million for FY2024, which is 633.51% down from last year.
- Per Foghorn Therapeutics' latest filing, its Accounts Payables stood at $9.8 million for Q3 2025, which was down 1245.21% from $8.6 million recorded in Q2 2025.
- Foghorn Therapeutics' Accounts Payables' 5-year high stood at $11.2 million during Q3 2024, with a 5-year trough of $2.9 million in Q1 2021.
- Moreover, its 5-year median value for Accounts Payables was $8.5 million (2024), whereas its average is $8.0 million.
- Per our database at Business Quant, Foghorn Therapeutics' Accounts Payables skyrocketed by 14081.07% in 2022 and then tumbled by 2905.67% in 2024.
- Over the past 5 years, Foghorn Therapeutics' Accounts Payables (Quarter) stood at $9.6 million in 2021, then grew by 15.05% to $11.0 million in 2022, then decreased by 17.21% to $9.1 million in 2023, then dropped by 6.34% to $8.5 million in 2024, then increased by 15.13% to $9.8 million in 2025.
- Its Accounts Payables was $9.8 million in Q3 2025, compared to $8.6 million in Q2 2025 and $6.5 million in Q1 2025.